NASDAQ: ONCT
Morningstar‘s Stock Analysis ONCT
Valuation
Currency in —
Is it the right time to buy or sell?
Is it the right time to buy or sell?
1-Star Price
INVESTOR
5-Star Price
INVESTOR
Economic Moat
INVESTOR
About Quantitative Ratings
Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
Unlock Our Full Analysis With Morningstar Investor
Company Profile ONCT
Business Description
Oncternal Therapeutics Inc is a clinical-stage oncology company developing first-in-class, novel therapies that target a broad spectrum of cancers with a large unmet medical need. The Company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. The Company is also developing ONCT-808, a CAR-T (chimeric antigen receptor T-cells) product candidate that targets ROR1 and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers.
Morningstar analysts hand-select direct competitors or comparable companies to provide context on the strength and durability of ONCT’s competitive advantage.
Oncternal Therapeutics Inc
XNAS: ONCT
| Eli Lilly and Co
XNYS: LLY
| Merck & Co Inc
XNYS: MRK
| AstraZeneca PLC
XLON: AZN
| |
Price
| 0.30 | 537.13 | 102.95 | 11,016.00 |
Currency
| USD | USD | USD | GBX |
Change
| $0.00 (1.35%) | −$7.32 (1.34%) | −$1.35 (1.29%) | −$86.00 (0.77%) |
Market Cap
| 17.69 Mil | 509.89 Bil | 261.24 Bil | 17.10 Tril |
Industry
| Biotechnology | Drug Manufacturers - General | Drug Manufacturers - General | Drug Manufacturers - General |
Sector
|
Healthcare
|
Healthcare
|
Healthcare
|
Healthcare
|
* Trading data in this section is delayed by at least 15 minutes.
FAQs for Oncternal Therapeutics Inc Stock
No. ONCT does not currently have a forward dividend yield.
Dividend yield allows investors, particularly those interested in dividend-paying stocks,
to compare the relationship between a stock’s price and how it rewards stockholders through dividends.
The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.
Learn more about dividend yield.
ONCT’s market cap is 17.69 Mil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares.
It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the
largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.
Learn more about market capitalization.
ONCT’s stock style is Small Value.
Style is an investment factor that has a meaningful impact on investment risk and returns.
Style is calculated by combining value and growth scores, which are first individually calculated.
High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.
Learn more about style.
ONCT’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.
Compare ONCT’s historical performance against its industry peers and the overall market.